HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toyomasa Katagiri Selected Research

Guanine Nucleotides

10/2021The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation.
9/2021Functional genomics for breast cancer drug target discovery.
10/2019Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction.
12/2017Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.
1/2015BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.
7/2014Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type α-helical structure.
8/2009Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toyomasa Katagiri Research Topics

Disease

71Neoplasms (Cancer)
09/2021 - 01/2002
40Breast Neoplasms (Breast Cancer)
10/2021 - 10/2004
23Carcinogenesis
02/2020 - 04/2003
9Synovial Sarcoma (Synovioma)
02/2022 - 10/2002
7Neoplasm Metastasis (Metastasis)
09/2021 - 02/2004
7Urinary Bladder Neoplasms (Bladder Cancer)
11/2018 - 04/2005
7Adenocarcinoma
12/2017 - 06/2002
7Renal Cell Carcinoma (Grawitz Tumor)
01/2017 - 06/2005
7Testicular Neoplasms (Testicular Cancer)
07/2012 - 09/2006
5Prostatic Neoplasms (Prostate Cancer)
01/2020 - 12/2003
5Lung Neoplasms (Lung Cancer)
04/2009 - 04/2003
5Pancreatic Neoplasms (Pancreatic Cancer)
11/2006 - 03/2004
4Hypoxia (Hypoxemia)
01/2017 - 06/2005
4Colorectal Neoplasms (Colorectal Cancer)
08/2012 - 02/2004
4Adenocarcinoma of Lung
04/2009 - 06/2002
3Osteosarcoma (Osteogenic Sarcoma)
10/2021 - 03/2004
3Sarcoma (Soft Tissue Sarcoma)
01/2013 - 10/2002
3Hepatocellular Carcinoma (Hepatoma)
02/2006 - 06/2003
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2012 - 07/2003
2Cysts
08/2008 - 03/2003
2Prostatic Intraepithelial Neoplasia
06/2005 - 09/2004
2Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
12/2004 - 12/2003
2Seminoma
12/2004 - 12/2003
2Uterine Cervical Neoplasms (Cancer of the Cervix)
09/2004 - 07/2002
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/2003 - 08/2002

Drug/Important Bio-Agent (IBA)

42Complementary DNA (cDNA)IBA
07/2017 - 01/2002
40Proteins (Proteins, Gene)FDA Link
10/2021 - 01/2003
20Small Interfering RNA (siRNA)IBA
02/2020 - 07/2004
12Peptides (Polypeptides)IBA
02/2020 - 07/2010
10Pharmaceutical PreparationsIBA
09/2021 - 01/2002
10AntigensIBA
07/2012 - 10/2004
8Estrogens (Estrogen)FDA Link
10/2021 - 08/2009
8Tumor Biomarkers (Tumor Markers)IBA
02/2014 - 06/2003
7Guanine NucleotidesIBA
10/2021 - 08/2009
7Brefeldin AIBA
10/2021 - 08/2009
6Biological ProductsIBA
02/2020 - 10/2002
6Phenobarbital (Luminal)FDA Link
12/2017 - 01/2013
6Estrogen ReceptorsIBA
06/2015 - 10/2004
5Phosphotransferases (Kinase)IBA
09/2021 - 04/2005
4Glycoproteins (Glycoprotein)IBA
02/2020 - 09/2007
4TamoxifenFDA LinkGeneric
12/2017 - 01/2007
4EpitopesIBA
01/2017 - 12/2004
4Oncogene Proteins (Oncogene Protein)IBA
01/2017 - 06/2005
4Cadherins (E-Cadherin)IBA
08/2012 - 04/2005
3Protein Kinases (Protein Kinase)IBA
09/2021 - 09/2003
3ErbB Receptors (EGF Receptor)IBA
09/2021 - 07/2003
3Biomarkers (Surrogate Marker)IBA
02/2020 - 09/2007
3LectinsIBA
02/2020 - 09/2007
3LigandsIBA
01/2020 - 12/2004
3Cisplatin (Platino)FDA LinkGeneric
11/2018 - 04/2003
3Estrogen Receptor alphaIBA
10/2018 - 08/2009
3Epidermal Growth Factor (EGF)IBA
05/2018 - 05/2015
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2017 - 01/2014
3human ERBB2 proteinIBA
06/2015 - 01/2014
3GlycosyltransferasesIBA
02/2014 - 04/2010
3Yttrium-90IBA
08/2012 - 02/2008
2Carrier Proteins (Binding Protein)IBA
02/2020 - 11/2010
2Messenger RNA (mRNA)IBA
01/2020 - 10/2004
2GemcitabineFDA Link
11/2018 - 04/2003
2Methotrexate (Mexate)FDA LinkGeneric
11/2018 - 04/2005
2Vinblastine (Vinblastine Sulfate)FDA Link
11/2018 - 04/2005
2Doxorubicin (Adriamycin)FDA LinkGeneric
11/2018 - 04/2005
2Polypeptide N-acetylgalactosaminyltransferaseIBA
10/2018 - 04/2010
2Radioisotopes (Radionuclides)IBA
06/2018 - 02/2008
2Leucine (L-Leucine)FDA Link
05/2018 - 12/2004
2Protein Subunit VaccinesIBA
03/2018 - 07/2012
2Hormones (Hormone)IBA
04/2017 - 08/2009
2xanthohumolIBA
04/2017 - 12/2014
2Mitogen-Activated Protein KinasesIBA
06/2015 - 04/2005
2ProhibitinsIBA
01/2015 - 12/2014
2DNA (Deoxyribonucleic Acid)IBA
01/2015 - 05/2012
2Monoclonal AntibodiesIBA
08/2012 - 02/2008
2Cancer VaccinesIBA
07/2012 - 11/2008
2PhosphoproteinsIBA
07/2012 - 04/2007
2beta CateninIBA
04/2010 - 03/2009
2BRCA1 ProteinIBA
11/2009 - 10/2002
2Membrane Proteins (Integral Membrane Proteins)IBA
07/2009 - 09/2005
2Calcibiotic Root Canal SealerIBA
03/2009 - 02/2004
2Cell Surface ReceptorsIBA
03/2009 - 09/2005
2KinesinsIBA
01/2008 - 01/2005
2Imatinib Mesylate (Gleevec)FDA Link
08/2007 - 08/2002
2AntibodiesIBA
09/2005 - 12/2004
2CollagenIBA
06/2005 - 04/2003
2Neoplasm Antigens (Tumor Antigens)IBA
12/2004 - 10/2004
2GlypicansIBA
12/2004 - 06/2003
2Tyrosine Kinase InhibitorsIBA
07/2003 - 08/2002
1Transcription Factors (Transcription Factor)IBA
01/2020
1ChemokinesIBA
01/2020
1Dopamine Receptors (Dopamine Receptor)IBA
11/2019
1Amino AcidsFDA Link
11/2019
1Interleukin-18 (Interleukin 18)IBA
09/2019
1Carboplatin (JM8)FDA LinkGeneric
11/2018
1RNA (Ribonucleic Acid)IBA
05/2018

Therapy/Procedure

22Therapeutics
09/2021 - 07/2003
16Lasers (Laser)
02/2013 - 06/2002
9Drug Therapy (Chemotherapy)
09/2021 - 01/2002
6Neoadjuvant Therapy
11/2018 - 03/2004
4Radioimmunotherapy
02/2022 - 02/2008
3Radiotherapy
09/2021 - 07/2002
3Immunotherapy
01/2014 - 10/2004